A randomized, double blind, placebo-controlled, phase 2a study of the efficacy, safety and pharmacokinetics of MLN3897 in patients with rheumatoid arthritis taking methotrexate.

Trial Profile

A randomized, double blind, placebo-controlled, phase 2a study of the efficacy, safety and pharmacokinetics of MLN3897 in patients with rheumatoid arthritis taking methotrexate.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2015

At a glance

  • Drugs MLN 3897 (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Millennium
  • Most Recent Events

    • 01 Dec 2010 Results published in Arthritis and Rheumatism.
    • 31 Jan 2010 Status changed from active, no longer recruiting to completed.
    • 10 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by Netherlands Trial Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top